Trevi Therapeutics Inc TRVI

NAS: TRVI | ISIN: US89532M1018   30/04/2025
6,910 USD (+9,51%)
(+9,51%)   30/04/2025

3 april 2025 · Trevi Therapeutics to Participate in Upcoming April Investor Conferences · Persbericht

18 maart 2025 · Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates · Persbericht

11 maart 2025 · Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 · Persbericht

10 maart 2025 · Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough · Persbericht

9 maart 2025 · Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough · Persbericht

4 september 2024 · Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 · Persbericht

28 augustus 2024 · Trevi Therapeutics to Participate in September Investor and Medical Conferences · Persbericht

8 augustus 2024 · Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance · Persbericht

1 augustus 2024 · Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 · Persbericht

2 juli 2024 · Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events · Persbericht

9 mei 2024 · Trevi Therapeutics to Participate in Upcoming Conferences · Persbericht

7 mei 2024 · Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates · Persbericht

1 mei 2024 · Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 · Persbericht

9 april 2024 · Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference · Persbericht

4 april 2024 · Trevi Therapeutics to Participate in Upcoming April Events · Persbericht

2 april 2024 · Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team · Persbericht

20 maart 2024 · Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates · Persbericht

13 maart 2024 · Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 · Persbericht

28 februari 2024 · Trevi Therapeutics to Participate in Upcoming March Events · Persbericht

6 februari 2024 · Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

Mijn selecties